286 related articles for article (PubMed ID: 28262261)
1. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
Quaranta S; Thomas F
Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics (RNPGx).
Woillard JB; Chouchana L; Picard N; Loriot MA;
Therapie; 2017 Apr; 72(2):285-299. PubMed ID: 28318610
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
6. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland ML; Vasisht K; Ratain MJ
Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
8. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
Iyer L
Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
[TBL] [Abstract][Full Text] [Related]
9. DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese LA; Lau-Min KS; Cambareri C; Damjanov N; Massa R; Reddy N; Oyer R; Teitelbaum U; Tuteja S
Pharmacotherapy; 2020 Nov; 40(11):1108-1129. PubMed ID: 32985005
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic applications in oncology.
Walko CM; Ikediobi O
J Pharm Pract; 2012 Aug; 25(4):439-46. PubMed ID: 22907843
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Innocenti F; Iyer L; Ratain MJ
Clin Pharmacokinet; 2000 Nov; 39(5):315-25. PubMed ID: 11108431
[TBL] [Abstract][Full Text] [Related]
12. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
Hasegawa Y
Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
[TBL] [Abstract][Full Text] [Related]
14. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
[TBL] [Abstract][Full Text] [Related]
15. Cancer pharmacogenetics.
Marsh S; McLeod HL
Br J Cancer; 2004 Jan; 90(1):8-11. PubMed ID: 14710198
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of clinical implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated patients.
Lunenburg CA; van Staveren MC; Gelderblom H; Guchelaar HJ; Swen JJ
Pharmacogenomics; 2016 May; 17(7):721-9. PubMed ID: 27181275
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).
Picard N; Boyer JC; Etienne-Grimaldi MC; Barin-Le Guellec C; Thomas F; Loriot MA;
Therapie; 2017 Apr; 72(2):185-192. PubMed ID: 28237406
[TBL] [Abstract][Full Text] [Related]
19. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
García-Alfonso P; Saiz-Rodríguez M; Mondéjar R; Salazar J; Páez D; Borobia AM; Safont MJ; García-García I; Colomer R; García-González X; Herrero MJ; López-Fernández LA; Abad-Santos F
Clin Transl Oncol; 2022 Mar; 24(3):483-494. PubMed ID: 34773566
[TBL] [Abstract][Full Text] [Related]
20. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions.
Wang L; Weinshilboum R
Oncogene; 2006 Mar; 25(11):1629-38. PubMed ID: 16550163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
